Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) EPS (Weighted Average and Diluted): 2016-2024

Historic EPS (Weighted Average and Diluted) for Corcept Therapeutics (CORT) over the last 9 years, with Dec 2024 value amounting to $1.23.

  • Corcept Therapeutics' EPS (Weighted Average and Diluted) fell 60.98% to $0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.87, marking a year-over-year decrease of 30.95%. This contributed to the annual value of $1.23 for FY2024, which is 30.85% up from last year.
  • As of FY2024, Corcept Therapeutics' EPS (Weighted Average and Diluted) stood at $1.23, which was up 30.85% from $0.94 recorded in FY2023.
  • Corcept Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at $1.23 during FY2024, with a 5-year trough of $0.85 in FY2020.
  • Over the past 3 years, Corcept Therapeutics' median EPS (Weighted Average and Diluted) value was $0.94 (recorded in 2023), while the average stood at $1.01.
  • As far as peak fluctuations go, Corcept Therapeutics' EPS (Weighted Average and Diluted) declined by 2.25% in 2022, and later skyrocketed by 30.85% in 2024.
  • Over the past 5 years, Corcept Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at $0.85 in 2020, then increased by 4.71% to $0.89 in 2021, then decreased by 2.25% to $0.87 in 2022, then climbed by 8.05% to $0.94 in 2023, then soared by 30.85% to $1.23 in 2024.